Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Consensus Target Price of $256.00 According to Brokerages

by · The Markets Daily

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) have earned a consensus rating of “Hold” from the nine analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $256.00.

GOSS has been the subject of a number of research reports. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a report on Tuesday, July 28th. Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th.

Read Our Latest Research Report on GOSS

More Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

  • Positive Sentiment: Gossamer Bio submitted a New Drug Application to the U.S. Food and Drug Administration for seralutinib, its lead candidate for pulmonary arterial hypertension. The filing represents a major development milestone and could improve the company’s long-term commercial prospects if accepted and ultimately approved. Gossamer Bio Submits New Drug Application to the FDA
  • Positive Sentiment: HC Wainwright maintained a “Buy” rating and raised several longer-term EPS forecasts, including estimates for 2027 through 2029. The revisions suggest the analyst expects improving financial performance as seralutinib advances toward potential commercialization. Gossamer Bio analyst estimates
  • Neutral Sentiment: Reports on September short interest are contradictory: one cites a sharp decline to 948,623 shares, while another reports zero shares short. The figures may reflect a reporting or corporate-action issue, so investors should verify the data before interpreting it as evidence of covering or short-squeeze potential.
  • Negative Sentiment: Despite the NDA milestone, reports indicated that Gossamer Bio’s stock fell following the FDA filing, suggesting a possible “sell-the-news” reaction or investor disappointment with the filing’s near-term impact. The company remains dependent on regulatory progress and has yet to generate commercial revenue. Gossamer Bio stock falls after FDA filing
  • Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast, as well as estimates for the fourth quarter of 2026 and first quarter of 2027. Although the firm remains bullish overall, the revisions highlight continued substantial losses and financing risk while Gossamer funds development.

Gossamer Bio Price Performance

GOSS opened at $10.93 on Friday. The business’s 50-day moving average price is $13.02 and its two-hundred day moving average price is $19.53. Gossamer Bio has a 1 year low of $9.10 and a 1 year high of $309.60. The company has a market capitalization of $32.02 million, a price-to-earnings ratio of -0.20 and a beta of 2.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd boosted its holdings in Gossamer Bio by 22.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after purchasing an additional 4,771 shares during the period. ProShare Advisors LLC grew its position in shares of Gossamer Bio by 39.6% during the 4th quarter. ProShare Advisors LLC now owns 45,338 shares of the company’s stock worth $141,000 after purchasing an additional 12,863 shares in the last quarter. Eaton Financial Holdings Company LLC bought a new position in shares of Gossamer Bio during the fourth quarter worth approximately $44,000. AXQ Capital LP increased its holdings in shares of Gossamer Bio by 36.1% during the fourth quarter. AXQ Capital LP now owns 63,117 shares of the company’s stock worth $196,000 after purchasing an additional 16,750 shares during the period. Finally, Rockefeller Capital Management L.P. raised its position in shares of Gossamer Bio by 496.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock valued at $189,000 after buying an additional 50,666 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.

Featured Stories